Event Type: Q1 FY27 Earnings Conference Call held on July 24, 2026, with a duration of 1 hour.
Management Participants: (Hony) Brig. Dr. Arvind Lal (Executive Chairman), Mr. Shankha Banerjee (Chief Executive Officer), and Mr. Ved Prakash Goel (Group CFO and CEO, International Business).
Purpose: Discussion of financial results for Q1 FY27 and strategic business updates.
Financial Highlights:
Revenue: ₹798 crore, up 19.1% YoY (₹670 crore in Q1 FY26)
EBITDA: ₹247 crore, up 28.7% YoY, with margin at 31.0%
PAT: ₹170 crore, up 27.2% YoY, with margin at 21.4%
EPS: ₹10.1, up 27.8% from ₹7.9
Patient volumes: 8.2 million, growth of 8.2%
Sample volumes: 25.9 million, growth of 10.7%
Revenue per patient: ₹968, up 10% from ₹880
Tests per patient: 3.14 vs 3.07
Net cash: ₹1,693 crore as of June 30, 2026
Strategic Updates:
Launched 116 new tests including 4 first-in-India tests
GenAI Patient Bot (SwasthAI) launched on WhatsApp
Rural outreach program active in 7 states with 110,000 patients tested
Wholly owned subsidiary incorporated in Dubai
Acquisitions:
80% stake in Sunshine Healthcare Limited, Ghana for up to GHS 45.6 million
30% stake in Neuome Technologies Private Limited for up to ₹3.5 crore
Dividend: Interim dividend of 50% (₹5 per share) declared
Guidance: Management indicated potential for mid-teens revenue growth (previously early teens) and maintained EBITDA margin guidance of 27%-28% with potential for reinvestment
Compliance: Standard forward-looking statement disclaimer was provided
Additional Notes Section
The document is a transcript of the earnings conference call submitted pursuant to Regulation 30 of SEBI LODR Regulations.
Financial data was extensively disclosed in the transcript including full quarterly results.
Multiple analysts from JM Financial, BNP Paribas, Haitong Securities, Emkay Global, and other institutions participated in the Q&A session.
